Welcome to our dedicated page for Nascent Biotech news (Ticker: NBIO), a resource for investors and traders seeking the latest updates and insights on Nascent Biotech stock.
Nascent Biotech, Inc. (NBIO) generates news primarily through developments in its clinical programs, collaborations, and corporate updates related to its lead monoclonal antibody candidate, Pritumumab (PTB). As a clinical-stage biotechnology company focused on cancer therapeutics, many of its announcements center on progress in brain cancer research, particularly glioblastoma, and on regulatory and scientific milestones.
News coverage for NBIO often highlights key clinical events, such as completion and presentation of Phase I trial data, FDA clearance to begin Phase II clinical trials for brain cancer, and updates on Phase II planning and study design. The company also issues press releases when it presents data at major scientific meetings, including poster presentations that summarize safety findings and early signs of biological activity.
Another important category of Nascent Biotech news involves strategic collaborations. The company has announced a research collaboration with Manhattan BioSolutions to explore antibody-drug conjugates using Pritumumab as the targeting antibody, and a collaboration with HypoSpray Pharma to investigate alternative transdermal and transmucosal delivery approaches for PTB. These stories provide insight into how Nascent aims to expand PTB’s potential applications and delivery options.
Investors following NBIO will also see corporate and capital-structure updates, such as the company’s disclosure that it fully repaid a variable convertible note to remove related dilution risk, and its later notice about a filing delinquency that led to quotation on the OTC Markets’ Expert Market. Together, these news items offer a view into both the scientific and financial aspects of Nascent Biotech’s development. This page aggregates such releases so readers can track clinical progress, partnership activity, regulatory milestones, and trading-status updates over time.
Nascent Biotech (OTCQB:NBIO) announced a Notice of Allowance from the USPTO for its lead candidate Pritumumab. This approval, related to patent application 17/515,010, secures broad protections for Pritumumab and its clinical storage conditions. Pritumumab is a naturally-derived antibody designed to target vimentin-expressing tumors, offering a novel approach to treatment that minimizes damage to healthy cells. The patent's allowance is a pivotal step for Nascent in establishing itself in the market of brain cancer therapeutics.
Nascent Biotech (OTCQB:NBIO) has completed the third cohort in its Phase I clinical trial for Brain Cancer, advancing toward the fourth and potentially final cohort. Although the third cohort took longer than expected, the data is deemed useful for future directions. Patient enrollment is ongoing, and the company plans to conduct pharmacokinetic studies to assess the need for a fifth cohort. Pritumumab (PTB) is a targeted immunotherapy designed to selectively target cancer cells without harming healthy cells, marking a significant advancement in cancer treatment.
Nascent Biotech (OTCQB:NBIO) announced that its CEO, Sean Carrick, was interviewed by Proactive Investors, discussing the company's progress with its Phase I Clinical Trial for Pritumumab (PTB), a monoclonal antibody targeting cancers originating in epithelial cells. Carrick emphasized the company's ongoing development of PTB, with plans to advance to Phase II trials, which could significantly benefit shareholders. The interview highlighted milestones achieved in monoclonal antibody development and a vaccine platform utilizing r-BCG to combat viral infections.
Nascent Biotech has announced a partnership with BioTools, focusing on the monoclonal antibody Pritumumab (PTB), aimed at treating brain cancer. This collaboration leverages BioTools' advanced ROA laser-based technology to enhance the characterization of PTB's higher-order molecular structure, potentially improving its effectiveness and applications. PTB, currently in Phase I clinical trials, is expected to benefit from BioTools' expertise in biologic characterization, aiding in the optimization of its pharmaceutical properties.
Nascent Biotech has partnered with Sharp HealthCare to initiate a Phase I clinical trial for Pritumumab (PTB), an innovative immunotherapy targeting glioblastoma, a severe brain cancer. This trial is designed to explore Pritumumab's efficacy against brain tumors and has potential implications for treating other epithelial cancers. Sharp HealthCare's robust cancer program is a key asset in this collaboration. The trial reflects a commitment to addressing significant unmet medical needs in oncology, with an estimated 23,000 new GBM cases annually in the U.S.
Nascent Biotech has received a milestone payment of USD $750,000 from BioRay Pharmaceutical as part of their licensing agreement for the monoclonal antibody Pritumumab. This payment marks the second of four payments totaling USD $5 million, following an initial USD $1 million received in April 2021. The next payment of USD $2.5 million is contingent upon FDA approval for a Phase 2 clinical trial, with the final USD $750,000 due upon trial commencement. Pritumumab is currently in Phase 1 trials targeting brain cancer.
Nascent Biotech (OTCQB:NBIO) has completed dosing for the second cohort in its Phase I trial evaluating Pritumumab (PTB) as a treatment for brain cancer. This achievement allows the company to advance to its third cohort, anticipated to commence shortly. PTB is a targeted immunotherapy designed to specifically attack cancer cells without harming healthy cells. Positive data trends have been reported, paving the way for a future petition for Phase 2 testing. The company continues to push forward in its mission to develop innovative cancer treatments.
Nascent Biotech (OTCQB:NBIO) and its partner, Manhattan BioSolutions, have reported promising preclinical results for a COVID-19 vaccine candidate based on a modified BCG vaccine originally developed for tuberculosis. The vaccine, termed BCG-S, demonstrated significant cellular immune responses in mice, indicating potential effectiveness. Moving forward, additional experiments will investigate the protective efficacy of this vaccine. Both companies express optimism about their collaboration and aim to advance innovative therapies to improve patient outcomes.
Nascent Biotech (OTCQB: NBIO) announced the release of an analyst report by Marble Arch Research, which rates the stock a Speculative Buy with a target price of $0.39 to $1.99. The report emphasizes the potential for significant market value growth as the company's lead drug, Pritumumab (PTB), progresses through clinical trials. Currently, PTB is in an FDA-approved Phase I trial targeting primary and metastatic brain cancer. The CEO expressed optimism for future developments in treating cancers and viral infections.
Nascent Biotech (OTCQB:NBIO) has commenced enrollment for the second cohort in its Phase I trial for treating Brain Cancer with its lead candidate, Pritumumab (PTB). This trial milestone allows for tripling dosage levels over the first cohort, targeting the highest dose without toxicity. PTB, a natural human antibody, targets Cell surface Vimentin to specifically attack cancer cells, sparing healthy ones. The ongoing Phase I trial signifies advancements in targeted immunotherapy, with development for COVID-19 also underway.